^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Promising response of dabrafenib, trametinib, and osimertinib combination therapy for concomitant BRAF and EGFR-TKI resistance mutations

Published date:
08/14/2023
Excerpt:
In conclusion, the combination therapy of osimertinib, dabrafenib, and trametinib shows promise as a targeted therapeutic option for patients with advanced NSCLC harboring both BRAF V600E and EGFR mutations.
DOI:
10.1097/CAD.0000000000001537
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Published date:
02/12/2021
Excerpt:
We report a case of impressive radiological and ctDNA response under dabrafenib, trametinib, and osimertinib in an advanced EGFR-mutant lung adenocarcinoma patient who developed BRAF V600E as one of the acquired resistance mechanisms to second-line osimertinib. Moreover, the patient experienced remarkable clinical improvement and good tolerance to combination therapy. 
DOI:
10.1038/s41698-021-00149-4